Sequencing HER2-targeting therapies in the metastatic breast cancer space

Treatment approaches in breast cancer are multimodal, and with the onset of novel immunotherapies and targeted agents, the therapeutic landscape of patients with advanced disease has expanded. In HER2+ disease, the treatment landscape has become saturated with novel HER2-targeting agents, bringing into question how these agents should be sequenced for maximum benefit to patients. In this podcast, we spoke with three leading experts in breast cancer who discuss the optimal sequencing of HER2-targeted therapies such as T-DM1, neratinib, tucatinib, and margetuximab. Join Lisa Carey, MD, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Hope Rugo, MD, FASCO, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, and Thomas Bachelot, MD, PhD, Centre Léon Bérard, Lyon, France, who outline decision making in the metastatic HER2+ breast cancer space, as well as how to sequence these novel agents.